Tarceva and Incontinence - a phase IV clinical study of FDA data

Summary:

Incontinence is reported as a side effect among people who take Tarceva (erlotinib hydrochloride), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Avastin, and have Hypercalcaemia of malignancy.

The phase IV clinical study analyzes which people have Incontinence when taking Tarceva. It is created by eHealthMe based on reports of 30,795 people who have side effects when taking Tarceva from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Incontinence?

Incontinence (lack of moderation or self-control) is found to be associated with 954 drugs and 1,123 conditions by eHealthMe. Check the latest studies of Incontinence.

On Jul, 29, 2026

30,795 people reported to have side effects when taking Tarceva.
Among them, 26 people (0.08%) have Incontinence.

Among these 26 people:

How long have people been on Tarceva when they have Incontinence? *

What is the gender of people who have Incontinence when taking Tarceva? *

female: 73.08 %
male: 26.92 %

What is the age of people who have Incontinence when taking Tarceva? *

What are other drugs people take besides Tarceva? *

What are other side effects people have besides Incontinence? *

Pain: 15 people, 57.69%
Back Pain: 14 people, 53.85%
Nosebleed (bleeding from nose): 14 people, 53.85%
Dizziness: 14 people, 53.85%
Weight Increased: 13 people, 50.00%
Tinnitus (a ringing in the ears): 13 people, 50.00%
Abdominal Pain: 12 people, 46.15%
Weight Decreased: 12 people, 46.15%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 12 people, 46.15%
Osteonecrosis Of Jaw (death of bone of jaw): 11 people, 42.31%

What are the existing conditions these people have? *

Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 10 people, 38.46%
Pain: 5 people, 19.23%
Rectal Cancer Metastatic (cancer of rectum spreads to other): 4 people, 15.38%
Lung Neoplasm Malignant (cancer tumour of lung): 4 people, 15.38%
Vestibular Disorder (disorders of the body's balance (vestibular) system in the inner ear): 3 people, 11.54%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 3 people, 11.54%
Lung Carcinoma Cell Type Unspecified Stage I (the lung cancer is small and hasn't spread to the lymph nodes): 3 people, 11.54%
Metastases To Bone (cancer spreads to bone): 3 people, 11.54%
Muscle Spasms (muscle contraction): 3 people, 11.54%
Neoplasm Malignant (cancer tumour): 3 people, 11.54%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and have Incontinence?

- Check whether Incontinence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarceva:

Tarceva (31,036 reports)

Incontinence treatments and more:

Incontinence (18,003 reports)

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Incontinence:

Incontinence (954 drugs)

Browse all the conditions that are associated with Incontinence:

Incontinence (1,123 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Tarceva) and Tarceva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.